We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.7B
AUM Growth
+$120M
Cap. Flow
-$25.9M
Cap. Flow %
-0.96%
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$17.5M
2
NVRO
NEVRO CORP.
NVRO
+$15.6M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$14.2M
4
NVS icon
Novartis
NVS
+$11.9M
5
BIIB icon
Biogen
BIIB
+$11.8M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.3M
2
MOH icon
Molina Healthcare
MOH
+$18.4M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.9M
4
PFE icon
Pfizer
PFE
+$11.2M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.69%
2 Real Estate 3.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADAP
76
DELISTED
Adaptimmune Therapeutics
ADAP
$6.58M 0.24%
1,466,368
– –
DXCM icon
77
DexCom
DXCM
$28.8B
$6.18M 0.23%
338,000
+53,200
+19% +$983K
THC icon
78
Tenet Healthcare
THC
$21.8B
$6.06M 0.22%
313,440
+148,940
+91% +$2.6M
CAH icon
79
Cardinal Health
CAH
$53.2B
$5.97M 0.22%
76,600
– –
WMGI
80
DELISTED
Wright Medical Group Inc
WMGI
$5.9M 0.22%
+214,781
New +$6.07M
UHS icon
81
Universal Health Services
UHS
$9.88B
$5.87M 0.22%
48,076
-104
-0.2% -$12.4K
SNR
82
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$5.71M 0.21%
567,997
– –
UTHR icon
83
United Therapeutics
UTHR
$26.2B
$5.7M 0.21%
43,961
– –
ENTL
84
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$5.66M 0.21%
+341,471
New +$4.75M
ESRX
85
DELISTED
Express Scripts Holding Company
ESRX
$5.39M 0.2%
+84,500
New +$5.31M
NTRA icon
86
Natera
NTRA
$38.6B
$5.28M 0.2%
485,758
-396,600
-45% -$3.87M
OVID icon
87
Ovid Therapeutics
OVID
$442M
$5.23M 0.19%
+535,824
New +$7M
MYOV
88
DELISTED
Myovant Sciences Ltd.
MYOV
$4.68M 0.17%
400,000
– –
AGN.PRA
89
DELISTED
Allergan plc
AGN.PRA
$4.34M 0.16%
5,000
– –
FOMX
90
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.32M 0.16%
930,398
– –
EPZM
91
DELISTED
Epizyme, Inc
EPZM
$4.24M 0.16%
281,000
-81,000
-22% -$1.22M
GBT
92
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.42M 0.13%
125,000
-47,500
-28% -$1.41M
DVAX
93
DELISTED
Dynavax Technologies
DVAX
$3.33M 0.12%
345,050
– –
ARDX icon
94
Ardelyx
ARDX
$1.25B
$3.26M 0.12%
639,370
– –
TVTX icon
95
Travere Therapeutics
TVTX
$5.33B
$3.26M 0.12%
167,949
– –
VRNA
96
DELISTED
Verona Pharma
VRNA
$3.21M 0.12%
+275,000
New +$3.64M
INVA icon
97
Innoviva
INVA
$1.57B
$3.19M 0.12%
248,803
– –
AFMD
98
DELISTED
Affimed
AFMD
$2.88M 0.11%
140,532
– –
PRGO icon
99
Perrigo
PRGO
$1.43B
$2.82M 0.1%
37,300
– –
SNDX icon
100
Syndax Pharmaceuticals
SNDX
$1.73B
$2.79M 0.1%
+200,000
New +$2.29M
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Tekla Capital Management held 152 positions worth $2.7B, up 4.7% from $2.58B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q2 2017 filing shows 13 new, 22 increased, 27 reduced and 8 closed positions. Its largest new stake was NEVRO CORP.: 194,621 shares worth $14.5M. The largest sale was Vertex Pharmaceuticals, an estimated $28.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2017 buy was NEVRO CORP.: 194,621 shares worth $14.5M.
  • Tekla Capital Management added most to Merck in Q2 2017, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $28.3M.
  • Tekla Capital Management fully exited Molina Healthcare in Q2 2017, selling an estimated $18.4M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.7B portfolio in Q2 2017.
  • Tekla Capital Management opened 13 new positions and closed 8 in Q2 2017.
  • Tekla Capital Management's portfolio value rose 4.7% quarter-over-quarter to $2.7B.

Based on Tekla Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.